US Patent 11136381 Anti-C3 antibodies

Patent 11136381 was granted and assigned to NGM Biopharmaceuticals on October, 2021 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

Patent

Patent attributes

Patent Applicant

NGM Biopharmaceuticals

Current Assignee

NGM Biopharmaceuticals

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

11136381

Date of Patent

October 5, 2021

Patent Application Number

20190401

Date Filed

April 1, 2019

Patent Citations Received

‌

US Patent 11767359 C3-binding agents and methods of use thereof

Patent abstract

The present disclosure provides binding agents, such as antibodies (including single chain variable fragments), that specifically bind complement component C3, including human C3, compositions comprising same, and methods of their use. The disclosure also provides related polynucleotides and vectors encoding the binding agents and cells comprising same.